Cantor Fitzgerald Boosts GH Research (NASDAQ:GHRS) Price Target to $35.00

GH Research (NASDAQ:GHRS) had its price target lifted by research analysts at Cantor Fitzgerald from $25.00 to $35.00 in a report issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 57.59% from the stock’s current price.

GHRS has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GH Research in a research report on Tuesday, April 21st. Guggenheim set a $34.00 price target on GH Research and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Royal Bank Of Canada lifted their price target on GH Research from $33.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Citigroup reaffirmed an “outperform” rating on shares of GH Research in a research report on Friday. Finally, HC Wainwright lifted their price target on GH Research from $35.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, GH Research has a consensus rating of “Moderate Buy” and an average target price of $41.00.

GH Research Stock Performance

Shares of NASDAQ GHRS opened at $22.21 on Friday. GH Research has a fifty-two week low of $9.52 and a fifty-two week high of $24.66. The firm has a market capitalization of $1.38 billion, a PE ratio of -27.76 and a beta of 1.27. The stock’s 50-day simple moving average is $17.03 and its 200-day simple moving average is $15.49.

GH Research (NASDAQ:GHRS) last issued its earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.04). On average, sell-side analysts forecast that GH Research will post -1.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC grew its stake in shares of GH Research by 63.4% in the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after purchasing an additional 822 shares during the last quarter. North Star Investment Management Corp. purchased a new position in shares of GH Research in the 1st quarter valued at approximately $31,000. Osaic Holdings Inc. grew its stake in shares of GH Research by 63.6% in the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after purchasing an additional 2,400 shares during the last quarter. Jefferies Financial Group Inc. grew its stake in shares of GH Research by 0.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company’s stock valued at $9,046,000 after purchasing an additional 2,988 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of GH Research in the 4th quarter valued at approximately $38,000. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.